|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5400
|
|
pubmed:dateCreated |
1999-1-28
|
|
pubmed:abstractText |
Current recombinant human immunodeficiency virus (HIV) gp120 protein vaccine candidates are unable to elicit antibodies capable of neutralizing infectivity of primary isolates from patients. Here, "fusion-competent" HIV vaccine immunogens were generated that capture the transient envelope-CD4-coreceptor structures that arise during HIV binding and fusion. In a transgenic mouse immunization model, these formaldehyde-fixed whole-cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HIV isolates from diverse geographic locations and genetic clades A to E. Development of these fusion-dependent immunogens may lead to a broadly effective HIV vaccine.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD4,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, env,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp120,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp41,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0036-8075
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
283
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
357-62
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9888845-AIDS Vaccines,
pubmed-meshheading:9888845-Animals,
pubmed-meshheading:9888845-Antigens, CD4,
pubmed-meshheading:9888845-Cell Fusion,
pubmed-meshheading:9888845-Coculture Techniques,
pubmed-meshheading:9888845-Epitopes,
pubmed-meshheading:9888845-Gene Products, env,
pubmed-meshheading:9888845-Giant Cells,
pubmed-meshheading:9888845-HIV Antibodies,
pubmed-meshheading:9888845-HIV Antigens,
pubmed-meshheading:9888845-HIV Envelope Protein gp120,
pubmed-meshheading:9888845-HIV Envelope Protein gp41,
pubmed-meshheading:9888845-HIV Infections,
pubmed-meshheading:9888845-HIV-1,
pubmed-meshheading:9888845-Humans,
pubmed-meshheading:9888845-Mice,
pubmed-meshheading:9888845-Mice, Transgenic,
pubmed-meshheading:9888845-Neutralization Tests,
pubmed-meshheading:9888845-Protein Conformation,
pubmed-meshheading:9888845-Receptors, CCR5,
pubmed-meshheading:9888845-Tumor Cells, Cultured
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
|
|
pubmed:affiliation |
The Montana Biotechnology Center and Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA.
|
|
pubmed:publicationType |
Journal Article,
Comment,
Research Support, U.S. Gov't, P.H.S.,
Retracted Publication,
Research Support, Non-U.S. Gov't
|
